Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

NCT07215767 | Recruiting Phase 3 FDA Drug

• 1 other identifier: 300140
• Study Type: interventional
• Target: 850
• Locations: 1 country
• Sites: 3

Brief Summary

The aim of this clinical study is to demonstrate the superior antihypersensitivity efficacy of a novel stannous fluoride (SnF2) and potassium nitrate (KNO3) dentifrice (Investigational Product), compared to SnF2 only, KNO3 only and Vehicle dentifrices, after 8 weeks twice daily use.

Conditions

Dentin Hypersensitivity

Outcome Measures

Primary Outcomes (2)

• Change from Baseline in Schiff sensitivity score at Week 8 (Test Dentifrice Versus [Vs] Reference Dentifrices 1, 2 and 3)

  Evaporative (air) sensitivity will be assessed by the participant's response to an evaporative (air) stimulus administered by the clinical examiner. Participant response will be evaluated immediately following application of the stimulus using the Schiff sensitivity scale (0=Participant does not respond to air stimulation, 1=Participant responds to air stimulus but does not request discontinuation of stimulus, 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus, 3=Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of stimulus). A decrease in Schiff sensitivity score indicates improvement. Schiff sensitivity score = mean score of the two 'Test Teeth' (selected at Baseline). Change from Baseline is calculated for each 'Test Tooth' first before calculating mean change for the two 'Test Teeth', where change from Baseline = Week 8 score minus Baseline score.

  Baseline and Week 8

• Change from Baseline in tactile threshold (grams [g]) at Week 8 (Test Dentifrice Vs Reference Dentifrices 1, 2 and 3)

  Tactile sensitivity will be assessed by the participant's response to a tactile stimulus administered by the clinical examiner using a constant pressure probe (Yeaple probe). After each application of the stimulus, the participant will be asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses will be recorded as the tactile threshold in g. At Baseline, upper force setting will be 20g; at Week 8, upper force setting will be 80g. An increase in tactile threshold (g) indicates improvement. Tactile threshold (g) = mean value for the two 'Test Teeth'. Change from Baseline is calculated for each 'Test Tooth' first before calculating mean change for the two 'Test Teeth', where change from Baseline in tactile threshold (g) at Week 8 = Week 8 value minus Baseline value.

  Baseline and Week 8

Secondary Outcomes (4)

• Change from Baseline in Schiff sensitivity score at Day 4, Week 1, Week 2 and Week 4 (Test Dentifrice Vs Reference Dentifrices 1, 2 and 3)

  Baseline, Day 4, Week 1, Week 2 and Week 4

• Change from Baseline in tactile threshold (g) at Day 4, Week 1, Week 2 and Week 4 (Test Dentifrice Vs Reference Dentifrices 1, 2 and 3)

  Baseline, Day 4, Week 1, Week 2 and Week 4

• Change from Baseline in Schiff sensitivity score at Day 4, Week 1, Week 2, Week 4 and Week 8 (Reference Dentifrices 1 and 2 Vs Reference Dentifrice 3)

  Baseline, Day 4, Week 1, Week 2, Week 4 and Week 8

• Change from Baseline in tactile threshold (g) at Day 4, Week 1, Week 2, Week 4 and Week 8 (Reference Dentifrices 1 and 2 Vs Reference Dentifrice 3)

  Baseline, Day 4, Week 1, Week 2, Week 4 and Week 8

Study Arms (4)

Test Dentifrice

EXPERIMENTAL

Participants will be instructed to dose the toothbrush head with the Test Dentifrice (at least a 1-inch strip of product), then brush the teeth thoroughly for at least 1-minute, twice a day (morning and evening) for approximately 8 weeks, making sure to brush all sensitive areas of the teeth.

Drug: Stannous fluoride and Potassium nitrate Dentifrice

Reference Dentifrice 1

ACTIVE COMPARATOR

Participants will be instructed to dose the toothbrush head with Reference Dentifrice 1 (at least a 1-inch strip of product), then brush the teeth thoroughly for at least 1-minute, twice a day (morning and evening) for approximately 8 weeks, making sure to brush all sensitive areas of the teeth.

Drug: Stannous fluoride Dentifrice

Reference Dentifrice 2

ACTIVE COMPARATOR

Participants will be instructed to dose the toothbrush head with Reference Dentifrice 2 (at least a 1-inch strip of product), then brush the teeth thoroughly for at least 1-minute, twice a day (morning and evening) for approximately 8 weeks, making sure to brush all sensitive areas of the teeth.

Drug: Potassium nitrate Dentifrice

Reference Dentifrice 3

PLACEBO COMPARATOR

Participants will be instructed to dose the toothbrush head with Reference Dentifrice 3 (at least a 1-inch strip of product), then brush the teeth thoroughly for at least 1-minute, twice a day (morning and evening) for approximately 8 weeks, making sure to brush all sensitive areas of the teeth.

Drug: Vehicle Dentifrice

Interventions

Vehicle Dentifrice DRUG

Placebo dentifrice

Reference Dentifrice 3

Stannous fluoride and Potassium nitrate Dentifrice DRUG

Fluoride dentifrice

Test Dentifrice

Stannous fluoride Dentifrice DRUG

Fluoride dentifrice

Reference Dentifrice 1

Potassium nitrate Dentifrice DRUG

Non-fluoride dentifrice

Reference Dentifrice 2

Eligibility Criteria

• Age: 12 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed and dated informed consent document (and assent document, if appropriate)
• Participant is biologically male or female.
• Participant is 12 to 65 years of age, inclusive, at the time of signing the consent/assent form.
• Participant is in good general, oral and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in self-reported medical history, or upon oral examination, that would impact their safety or well-being, or the outcomes of the study, if they were to participate in the study, or affect their ability to understand and follow study requirements.
• Participant has a history of tooth sensitivity lasting more than six months but not more than 10 years (self-reported).
• Participant has a minimum of 2 non-adjacent teeth (incisors, canines or premolars), in different quadrants, with exposed dentin due to facial/cervical erosion, abrasion or gingival recession, and clinically confirmed dentin hypersensitivity to tactile and evaporative (air) stimuli at Screening and Baseline.

You may not qualify if:

• Female participant who is pregnant at Screening and Baseline, or is intending to become pregnant during the study.
• Female participant who is breastfeeding.
• Participant with known or suspected intolerance or hypersensitivity to any of the study products, any of their stated ingredients or closely related compounds.
• Participant is participating in, or has participated in, other studies (including non-medicinal studies) involving an Investigational Product within 30 days of Screening or plans to participate in other studies (including non-medicinal studies) during this study.
• Participant has participated in a tooth sensitivity study within 8 weeks of Screening.
• Participant is currently using an oral care product indicated for dentin hypersensitivity relief or care of sensitive teeth or has used an antihypersensitivity oral care product within 8 weeks of Screening.
• Participant takes daily doses of medications/treatments which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of tooth sensitivity.
• Participant has had professional tooth de-sensitising treatment within 8 weeks of Screening.
• Participant has had a tooth bleaching procedure within 8 weeks of Screening.
• Participant has had dental prophylaxis within 4 weeks of Screening.
• Participant with evidence of gross intra-oral neglect or the need for extensive dental therapy.
• Participant with evidence of current/recent active dental caries or treatment for decay within 12 months of Screening.
• Participant who, in the opinion of the investigator or dentally qualified designee, is at high risk of dental caries.
• Participant has taken antibiotics in the 2 weeks prior to Screening or Baseline.

Sponsors & Collaborators

• HALEON: lead

Study Sites (3)

All Sum Research Limited

Melbourne, Florida, 32935, United States

RECRUITING

Salus Research, Inc.

Fort Wayne, Indiana, 46825, United States

RECRUITING

Silverstone Research

Las Vegas, Nevada, 89146, United States

RECRUITING

MeSH Terms

Conditions

Dentin Sensitivity

Interventions

Tin Fluorides

Condition Hierarchy (Ancestors)

Tooth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Fluorides; Hydrofluoric Acid; Fluorine Compounds; Inorganic Chemicals; Tin Compounds; Cariostatic Agents; Biomedical and Dental Materials; Manufactured Materials; Technology, Industry, and Agriculture

Study Officials

• Pejmon Amini

  Silverstone Research

  PRINCIPAL INVESTIGATOR

• Jeffery L Milleman

  Salus Research, Inc

  PRINCIPAL INVESTIGATOR

• John T Gallob

  All Sum Research

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Haleon Response Center

CONTACT

+441932959500; ww.clinical-trial-register@haleon.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2025
• First Posted: October 10, 2025
• Study Start: September 16, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: February 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: IPD will be made available within 6 months of publishing the results of the primary and key secondary endpoints and the safety data for the study.
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Locations

US (3)